Financial reports
10-Q
2024 Q1
Quarterly report
12 Feb 24
10-K
2023 FY
Annual report
18 Dec 23
10-Q
2023 Q3
Quarterly report
8 Aug 23
10-Q
2023 Q2
Quarterly report
10 May 23
10-Q
2023 Q1
Quarterly report
8 Feb 23
10-K
2022 FY
Annual report
13 Dec 22
10-Q
2022 Q3
Quarterly report
10 Aug 22
10-Q
2022 Q2
Quarterly report
12 May 22
10-Q
2022 Q1
Quarterly report
14 Mar 22
Current reports
8-K
Departure of Directors or Certain Officers
21 Jun 24
8-K
Regulation FD Disclosure
24 May 24
8-K
Regulation FD Disclosure
24 Apr 24
8-K
Regulation FD Disclosure
26 Mar 24
8-K
Entry into a Material Definitive Agreement
28 Feb 24
8-K
Regulation FD Disclosure
27 Feb 24
8-K
Entry into a Material Definitive Agreement
22 Feb 24
8-K
Regulation FD Disclosure
25 Jan 24
8-K
Regulation FD Disclosure
21 Dec 23
8-K
Regulation FD Disclosure
27 Nov 23
Registration and prospectus
424B3
Prospectus supplement
16 May 24
SC TO-I
Issuer tender offer statement
15 May 24
SC TO-I/A
Issuer tender offer statement (amended)
9 May 24
424B3
Prospectus supplement
15 Feb 24
SC TO-I
Issuer tender offer statement
15 Feb 24
SC TO-I/A
Issuer tender offer statement (amended)
1 Feb 24
424B3
Prospectus supplement
21 Dec 23
SC TO-I
Issuer tender offer statement
15 Nov 23
424B3
Prospectus supplement
14 Nov 23
SC TO-I/A
Issuer tender offer statement (amended)
26 Oct 23
Proxies
No filings
Ownership
4
IMPEL PHARMACEUTICALS INC
4 Dec 23
3
IMPEL PHARMACEUTICALS INC
20 Nov 23
SC 13D
OAKTREE FUND GP I, L.P.
15 Mar 22
4
Change in insider ownership
9 Mar 22
3
Ashley Pak
3 Feb 22
3
Deborah Ann Gero
3 Feb 22
3
Steve Mosko
3 Feb 22
3
Initial statement of insider ownership
3 Feb 22
3
Armen Panossian
3 Feb 22
3
Allison Keller
3 Feb 22